Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 15/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 6/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29370567 | 1.00 | HDAC4 (1.00) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL2225769 | 0.94 | HDAC4 (0.89) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL29757316 | 0.94 | HDAC4 (0.88) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL2226555 | 0.93 | HDAC4 (0.87) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL14605297 | 0.91 | HDAC4 (0.82) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL14752448 | 0.88 | HDAC4 (0.79) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL2228678 | 0.86 | HDAC4 (0.76) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL2362796 | 0.83 | HDAC4 (0.71) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL25049598 | 0.83 | HDAC8 (0.71) | HDAC4HDAC1HDAC8HDAC7HDAC5 | |
| SCHEMBL14752493 | 0.83 | HDAC4 (0.71) | HDAC4HDAC1HDAC8HDAC7HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018057933-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR REDUCING OXIDATIVE STRESS IN CARDIOMYOCYTES | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2018-03-29 | — | — | WO | claimed |
| EP-2533783-B1 | COMPOUNDS AND METHODS for the inhibition of HDAC | TEMPERO PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | claimed |
| US-8901156-B2 | Compounds and methods | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | claimed |
| US-20130059883-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | claimed |
| WO-2013009830-A1 | METHODS OF TREATMENT | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | WO | claimed |
| WO-2013009810-A1 | METHODS OF TREATMENT | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | WO | claimed |
| US-12637433-B2 | Histone deacetylase inhibitors | THE UNIVERSITY OF QUEENSLAND (AU) | 2026-05-26 | — | — | US | disclosed |
| US-20240109847-A1 | HISTONE DEACETYLASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2024-04-04 | — | — | US | disclosed |
| EP-4267539-A1 | HISTONE DEACETYLASE INHIBITORS | The University of Queensland (AU) | 2023-11-01 | — | — | EP | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| WO-2022133551-A1 | HISTONE DEACETYLASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2022-06-30 | — | — | WO | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| WO-2011088181-A9 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| WO-2011088181-A9 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013009810-A1 | METHODS OF TREATMENT | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | WO | disclosed |
| WO-2013009830-A1 | METHODS OF TREATMENT | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | WO | disclosed |
| EP-2533783-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | HDAC4 2054/4885HDAC1 1578/4885HDAC8 1533/4885 |
| US-12637433-B2 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC3 | HDAC4 10/4885HDAC1 1/4885HDAC8 4/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | HDAC4 2054/4885HDAC1 1578/4885HDAC8 1533/4885 |
| US-20130059883-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | HDAC4 1441/4885HDAC1 640/4885HDAC8 1583/4885 |
| US-20240109847-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC11 | HDAC4 10/4885HDAC1 1/4885HDAC8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.